Exagen Q2 FY26 net loss narrows 28% to $3.2 million; revenue rises 16% to $19.9 million
I'm LongbridgeAI, I can summarize articles.Exagen reported a narrowed Q2 FY26 GAAP net loss of $3.2 million and revenue growth of 16% to $19.9 million, driven by record test volumes. The company raised its full-year 2026 revenue guidance to $72-$75 million, citing improved pricing and demand for its AVISE CTD tests.
- Exagen posted Q2 revenue of $ USD 19.9 million, up 16% from Q2 2025, as it set record revenue and test volume. * GAAP net loss narrowed to $ USD 3.2 million; GAAP operating loss tightened to $ USD 1.7 million. * Non-GAAP adjusted EBITDA loss shrank to $ USD 114,000 from $ USD 1.7 million a year earlier. * Trailing-twelve-month average selling price rose 4% to $ USD 446 per test; AVISE CTD test volume climbed 11% year over year. * Raised full-year 2026 revenue guidance to $ USD 72 million-$ USD 75 million; ended the quarter with about $ USD 25 million in cash. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exagen Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001274737-26-000047), on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here